Progenics Pharmaceuticals, Inc.

Type: Public
On the web: http://www.progenics.com
Employees: 105
Employee growth: (34.0%)

Progenics Pharmaceuticals is taking a proactive approach to fighting serious diseases. The company develops biotech drugs with oncology and virology applications, as well as therapeutics used in clinical care settings. Progenics' commercial product Relistor, which blocks the side effects of opioids without lessening their pain-killing power, is approved as an injectable treatment for opioid-induced constipation (OIC) in terminally ill patients. The drug was developed in collaboration with Wyeth Pharmaceuticals (now part of Pfizer). Also in the firm's pipeline are a therapeutic vaccine for prostate cancer, as well as a monoclonal antibody for treating HIV. Progenics was founded by Paul Maddon, M.D., Ph.D. in 1986.

Key numbers for fiscal year ending December, 2011:
Sales: $84.8M
One year growth: 966.3%
Net income: $10.4M

Officers:
Chairman: Peter J. Crowley
CEO, General Counsel, Secretary, and Director: Mark R. Baker
SVP Finance and Operations, CFO, Treasurer, and Secretary: Robert A. McKinney

Competitors:
Adolor
Pfizer
Takeda Pharmaceutical